00512 PE Ratio & Valuation, Is 00512 Overvalued

Historical Valuation

GRAND PHARMA (00512) is now in the Fair zone, suggesting that its current forward PE ratio of 12.79 is considered Fairly compared with the five-year average of 9.00. The fair price of GRAND PHARMA (00512) is between -- to -- according to relative valuation method.

Relative Value

Fair Zone

-----

Current Price：7.38

Fair

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is GRAND PHARMA (00512) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

GRAND PHARMA (00512) has a current Price-to-Book (P/B) ratio of 1.63. Compared to its 3-year average P/B ratio of 1.20, the current P/B ratio is approximately 35.53% higher. Relative to its 5-year average P/B ratio of 1.32, the current P/B ratio is about 23.92% higher. GRAND PHARMA (00512) has a Forward Free Cash Flow (FCF) yield of approximately 4.34%. Compared to its 3-year average FCF yield of 7.90%, the current FCF yield is approximately -45.07% lower. Relative to its 5-year average FCF yield of 7.94%, the current FCF yield is about -45.31% lower.

Performance Decomposition

AI Analysis

Market capitalization of 00512 increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of 00512 in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is 00512 currently overvalued or undervalued?

What is GRAND PHARMA (00512) fair value?

00512's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of GRAND PHARMA (00512) is between to according to relative valuation method.

How does 00512's valuation metrics compare to the industry average?

The average P/S ratio for 00512's competitors is 0.00, providing a benchmark for relative valuation. GRAND PHARMA Corp (00512) exhibits a P/S ratio of --, which is 0% above the industry average. Given its robust revenue growth of 0%, this premium appears unsustainable.

What is the current P/B ratio for GRAND PHARMA (00512) as of Mar 10 2026?

As of Mar 10 2026, GRAND PHARMA (00512) has a P/B ratio of 1.63. This indicates that the market values 00512 at 1.63 times its book value.

What is the current FCF Yield for GRAND PHARMA (00512) as of Mar 10 2026?

As of Mar 10 2026, GRAND PHARMA (00512) has a FCF Yield of 4.34%. This means that for every dollar of GRAND PHARMA's market capitalization, the company generates 4.34 cents in free cash flow.

What is the current Forward P/E ratio for GRAND PHARMA (00512) as of Mar 10 2026?

As of Mar 10 2026, GRAND PHARMA (00512) has a Forward P/E ratio of 12.79. This means the market is willing to pay $12.79 for every dollar of GRAND PHARMA's expected earnings over the next 12 months.

What is the current Forward P/S ratio for GRAND PHARMA (00512) as of Mar 10 2026?

As of Mar 10 2026, GRAND PHARMA (00512) has a Forward P/S ratio of 2.17. This means the market is valuing 00512 at $2.17 for every dollar of expected revenue over the next 12 months.

00512 Valuation